Use of Ginger Essential Oil with Cephalosporin antibiotics as Beta-Lactamase inhibitors in pharmaceutical design to fight Escherichia coli UTI-Reference-Cited by-同舟云学术

Use of Ginger Essential Oil with Cephalosporin antibiotics as Beta-Lactamase inhibitors in pharmaceutical design to fight Escherichia coli UTI

Published:2022-12-15 Issue:4 Volume:7 Page:1-5
ISSN:1390-9347
Container-title:Bionatura
language:
Short-container-title:RB

Author:

J. Khalil Yasmin¹,Saadedin Shurook M.K.¹

Affiliation:

1. Institute of Genetic Engineering and Biotechnology - University of Baghdad

Abstract

This research aimed to investigate multi-target inhibitors against the Beta-Lactamases protein of urinary tract infections (UTI) Escherichia coli, which is considered the main virulence factor of this bacterium. Drug design is regarded as a new approach to drug discovery and industry. The combination of Ginger Essential Oil (GEO) and Cefepime (FEP) showed effective results against Beta-Lactamase enzymes of UTI E.coli, 512 FEP+ 100% GEO and 1024 FEP + 100% GEO for (20 mm and 26 mm) inhibition zone respectively. The present study concluded that the isolates of E.coli of UTI from Iraqi hospitals were MDR and XDR, and their virulence was due to the presence of blaTEM genes. In silico screening, servers have been used to design an inhibitor model for Beta-Lactamases from the natural product of GEO. Cefepime and Ginger's essential oil showed a strong synergistic effect on these bacteria. Keywords: Escherichia coli; ESBLs; Ginger Essential Oil; Cefepime; UTI

Publisher

Clinical Biotec

Subject

Infectious Diseases,Applied Microbiology and Biotechnology,Epidemiology,Biotechnology

Reference23 articles.

1. 1. Kim, Y.; Yang, E. and Kim, J. Urinary tract infection caused by community-acquired extended-spectrum β-lactamase-producing bacteria in infants. J Pediatr, 2017; 93 (3):260-266.

2. 2. Alfredo, V.; Mercita, Q.; Amante, P.; Cabatu, J. and Gabriel, P. Bactericidal Property of Zingiber officinale (Ginger) Extract Against Staphylococcus aureus, Methicillin Resistant Staphylococcus aureus (MRSA), Escherichia coli and Extended Spectrum Beta Lactamase Escherichia coli,2021; 25 (4): 20548 – 20561.

3. 3. Vachvanichsanong, P.; McNeil, EB. and Dissaneewate, P. Extended-Spectrum Beta-Lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiology and Infection, 2021;149 (12):1–7.

4. 4. Bhattacharjee, A.; Sen, M.; Prakash, P.; Gaur, A. and Anupurba, S. Increased prevalence of Extended Spectrum Βeta-Lactamase producers in neonatal septicaemic cases at a tertiary referral hospital. Indian Journal of Medical Microbiology,2008; 26 (4): 356-360.

5. 5. Uemura, S.; Yokota, S.I.; Shiraishi, T.; Kitagawa, M.; Hirayama, S. and et al. Adaptive Cross-Resistance to Aminoglycoside Antibiotics in Pseudomonas aeruginosa Induced by Topical Dosage of Neomycin. Chemotherapy, 2017; 62 (2): 121-127.